表紙:人工血管市場 - 予測(2021年~2026年)
市場調査レポート
商品コード
1023201

人工血管市場 - 予測(2021年~2026年)

Vascular Graft Market - Forecasts from 2021 to 2026

出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
人工血管市場 - 予測(2021年~2026年)
出版日: 2021年10月01日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の人工血管の市場規模は、2019年の56億3700万米ドルから2026年には79億5500万米ドルに達し、予想期間中に5.04%のCAGRで成長すると予想されています。

人工血管は、感染したり傷ついたりした静脈を慎重に治療し、静脈を補うことで血流を再構築する有意な技術です。がんじょうな静脈を理想的に補うことは、将来への発展を約束します。これにより耐性のある健康をさらに自由に選ぶ機会が生まれます。

心血管感染症、腎不全、静脈疾患の患者数の増加、世界的な高齢者人口の増加、予防医療に対する公的機関の関心の高まり、堅実な将来への重要性の高まり、医療サービス管理にアクセスするためのダイレクト・ツー・ショッパー・アプローチの採用の拡大などは、2021年から2028年までの予想期間に人工血管市場の発展を促進させる可能性のある主要な要素です。また、診査活動の拡大、分離精度の向上、カスタマイズされた薬剤の使用など、自由度の高さが今後数年間の人工血管市場の発展を促すでしょう。

しかし、様々な企業が提供するグラフトのコストが不安定であることや、検査の輸送問題が拡大していることは、前述の予想期間において、人工血管市場の発展を制限する要因となる可能性があります。返済戦略の不在は、市場の発展にとって最大かつ重要な試練となるでしょう。

当レポートでは、世界の人工血管市場を調査し、市場の概要や動向、企業間の競合状況、素材別・適応症別・地域別での市場分析などの情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション

第2章 調査手法

  • 調査データ
  • 仮定

第3章 エグゼクティブサマリー

  • 調査のハイライト

第4章 市場力学

  • 市場の推進力
  • 市場の抑制要因
  • ポーターのファイブフォース分析
    • 供給企業の競争力
    • 購入企業の競争力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 機能における競争企業間の競争関係
  • 機能バリューチェーン分析

第5章 素材別:人工血管市場の分析

  • イントロダクション
  • 人工
  • ハイブリッド
  • 生体素材

第6章 適応症別:人工血管市場の分析

  • イントロダクション
  • 心血管疾患
  • 腎疾患
  • 動脈瘤
  • その他

第7章 エンドユーザー別:人工血管市場の分析

  • イントロダクション
  • 病院とクリニック
  • 外来手術センター

第8章 地域別:人工血管市場の分析

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • その他
  • 中東とアフリカ
    • イスラエル
    • サウジアラビア
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • 台湾
    • タイ
    • インドネシア
    • その他

第9章 競合環境と分析

  • 主要企業と戦略分析
  • 新興企業と市場の収益性
  • 合併、買収、合意、共同研究
  • ベンダー競争力 マトリックス

第10章 企業プロファイル

  • Hancock Jaffe Laboratories, Inc.
  • Getinge Group
  • W. L. Gore & Associates
  • Vascular Flow Technologies
  • C. R. Bard, Inc.
  • Artegraft Inc.
  • Vascular Genesis
  • B. Braun Melsungen AG
  • LeMaitre Vascular, Inc.
  • Terumo Aortic
目次
Product Code: KSI061611564

The global vascular graft market is projected to grow at a CAGR of 5.04% to reach US$7.955 billion by 2026, from US$5.637 billion in 2019

A vascular graft is a surgical technique that reconnects blood arteries to shift blood flow from one part of the body to another. The most common reason for vascular grafting is to increase blood flow to an organ fed by a damaged artery by bypassing a total or partial obstruction. These grafts range in size from 5-8 mm in diameter. This allows the body's blood flow to return to normal. Catheter-based devices are inserted through a small incision and guided with the use of real-time imaging technology in vascular transplant surgeries. Development of efficient and advanced novel products using tissue-engineered and biological materials, increased public awareness of peripheral artery diseases and coronary diseases, increased government initiatives around the world propel the global vascular graft market during the forecast period. The major growth drivers of the vascular graft market are the growing incidence of cardiovascular illnesses such as hypertension, coronary artery disease, and cardiac aneurysms, as well as the rising prevalence of diabetes. Moreover, increased vascular graft usage in emerging nations such as China, India, and others would open up new potential for the vascular graft market.

The vascular graft market growth is anticipated to be further aided by the rise in the senior population, technological improvements, and changes in lifestyle (consumption of junk food, cigarettes, and alcohol). The growing prevalence of end-stage renal diseases (ESRD) has further boosted the demand for vascular grafting during the forecast period. Dialysis, which is often used by individuals with ESRD, is the sole option for kidney transplantation. Three times a week, hemodialysis is performed. Many patients' superficial veins have been depleted as a result of continuous dialysis, and vascular grafts are the only way to continue hemodialysis. In 2017, 124,500 new cases of ESRD were reported in the United States, with a crude (uncorrected) incidence rate of 370.2 per million per year. The number of people living with ESRD is increasing at a rate of around 20,000 each year.

Due to strong medical reimbursement facilities and technical advancements, North America has anticipated led the vascular graft industry. Due to a rapidly growing geriatric population, increased consumer awareness, increased healthcare expenditure, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing countries such as China and India in this region, Asia Pacific is expected to grow at the fastest rate. The increased incidence of CKD, healthcare reforms, government efforts and investments, and rapid growth in the elderly population are all contributing to the Asia Pacific market's expanding growth. In addition, emerging markets such as Australia, Singapore, Japan provide various development possibilities for vascular grafts market participants because of an aging population and an increase in end-stage renal disease.

Growth Factors

The growing requirement for hemodialysis will fuel demand for vascular grafts

One of the major reasons for the growth of the global vascular graft market is the growing demand for hemodialysis. The growing need for hemodialysis products will boost demand for vascular grafts and propel the sector forward. Dialysis operations will become more common as the number of people with end-stage renal illness rises, as will the number of people with chronic kidney disease. Hemodialysis patients also require a well-functioning arteriovenous graft for a successful hemodialysis operation. According to research from the National Renal Foundation, 785,883 Americans suffered kidney failure in 2018 and required dialysis or a kidney transplant to live. As a result, the rising prevalence of chronic renal disease will lead to an increase in the number of hemodialysis procedures. Cook Medical's Zenith fenestrated endovascular graft earned FDA breakthrough device designation in March 2021. For life-threatening or profoundly disabling diseases or conditions, the product delivers more effective therapy or diagnosis. This strategy is anticipated to add value to the company's current portfolio while also generating money through sales. Furthermore, the increasing prevalence of cardiovascular illnesses throughout the world will drive up demand for vascular grafts.

Restraints

Product recalls and failures to hinder the market growth during the forecast period.

A major restraint in the growth of the global vascular graft market is the product recalls and failures limiting the adoption of vascular graft during the forecast period. Patients might suffer serious or even fatal consequences as a result of product failures. Several businesses' goods have been recalled from the market throughout the years owing to product faults or other concerns. End-user perceptions of graft safety may be harmed as a result of market trends, which may influence their acceptance in treatment processes. As a result, the adoption of vascular grafts has been restrained during the forecast period.

COVID-19 Impact

The COVID-19 pandemic has had a great impact on the world as a whole and has led to economic breakdown and loss of life. Production activities are interrupted because of lockdown measures enforced in numerous countries. The COVID-19 impact on the global vascular graft market has been adverse owing to the production halt by industries due to the temporary lockdown implemented by several governments to break the cycle of the virus. The disruption in the demand and supply chain has further hampered the market in the forecast period. Despite the availability of OPD administrations at emergency clinics, the number of patient visits to clinics has fallen significantly in recent months. Despite this, patient visits to medical facilities have fallen significantly as a result of the lockdown in several countries. As a result, the number of suggestive tests has decreased. The sale of vascular grafts has also decreased as a result of this. Since the majority of vascular grafts and interventional techniques are elective, many of these procedures have been postponed. This is another issue that has a negative impact on the market for vascular grafts. However, in the post-COVID-19 scenario, the global vascular graft market is expected to boom with the increasing demand during the forecast period.

Competitive Insights

The market leaders for the pretreatment coating market are Hancock Jaffe Laboratories Inc., Getinge Group, W.L. Gore & Associates, Vascular Flow Technologies, C.R. Bard Inc., Artegraft Inc., Vascular Genesis, B. Braun Melsungen AG, LeMaitre Vascular Inc., and Terumo Aortic.

Segmentation:

By Source

  • Synthetic
  • Semi-Synthetic
  • Natural

By Indication

  • Cardiovascular Diseases
  • Renal Diseases
  • Aneurysms
  • Others

By End-Users

  • Hospitals and Clinics
  • Ambulatory Surgical Centers

By Geography

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Indonesia
    • Taiwan
    • Thailand
    • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Vascular Graft Market Analysis, By Source

  • 5.1. Introduction
  • 5.2. Synthetic
  • 5.3. Semi-Synthetic
  • 5.4. Natural

6. Vascular Graft Market Analysis, By Indication

  • 6.1. Introduction
  • 6.2. Cardiovascular Diseases
  • 6.3. Renal Diseases
  • 6.4. Aneurysms
  • 6.5. Others

7. Vascular Graft Market Analysis, By End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Ambulatory Surgical Centers

8. Vascular Graft Market Analysis, By Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. France
    • 8.4.3. Germany
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. Israel
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. South Korea
    • 8.6.6. Thailand
    • 8.6.7. Taiwan
    • 8.6.8. Indonesia
    • 8.6.9. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles

  • 10.1. Hancock Jaffe Laboratories Inc.
  • 10.2. Getinge Group
  • 10.3. W.L. Gore & Associates
  • 10.4. Vascular Flow Technologies
  • 10.5. C.R. Bard Inc.
  • 10.6. Artegraft Inc.
  • 10.7. Vascular Genesis
  • 10.8. B. Braun Melsungen AG
  • 10.9. LeMaitre Vascular Inc.
  • 10.10. Terumo Aortic